Hormona Gonadotropina Coriónica Humana detectada en los controles Antidopaje en el Fútbol Sudamericano Masculino – Periodo 2014 - 2023.

Osvaldo Miguel Pangrazio Kullak; Francisco Luis Forriol Campos; Gabriela Gossen Spatuzza

doi:10.59856/arch.soc.chil.med.deporte.v68i2.72

Authors

Osvaldo Miguel Pangrazio Kullak Medico. Unidad Antidopaje de la Confederación Sudamericana de Fútbol. Paraguay
Francisco Luis Forriol Campos Medico. Unidad Antidopaje de la Confederación Sudamericana de Fútbol. Paraguay
Gabriela Gossen Spatuzza Unidad Antidopaje de la Confederación Sudamericana de Fútbol. Paraguay

DOI:

https://doi.org/10.59856/arch.soc.chil.med.deporte.v68i2.72

Keywords:

Chorionic Gonadotropin Hormone, Anti-doping, Football, Testicular cancer

Abstract

Introduction: Chorionic Gonadotropin Hormone (CGH) is one of the elements to be detected in anti-doping controls in football, as it is included in the 2023 Prohibited List of the World Anti-Doping Agency (AMA-WADA), in group S2 Peptide Hormones, growth factors, related substances and mimetics. Elevated amounts of HCG can be a diagnosis of testicular cancer. The objective of the study is to determine the frequency of detection of high amounts of HGC in male players in CONMEBOL soccer competitions to notify it to the player and establish the diagnosis with specialized studies.

Material and methodology: Prospective observational cases reports, between January 2014 and March 2023, when 18,110 urine and blood anti-doping controls were carried out in all official CONMEBOL: field, futsal and beach-football matches, following the CONMEBOL protocol. The urine was analyzed in accredited laboratories as established by the WADA Technical Document – TD2021CG/LH. HGC values were analyzed in all anti-doping controls carried out to determine those with high amounts of HGC in urine.

Results: High samples were found in two cases (0.01%) and we proceeded in accordance with those established in the results management procedure for this type of case; The player was notified and specialized medical studies were requested to corroborate or rule out a possible case of testicular tumor. In both cases, testicular seminoma with increased ß-HCG was confirmed. Testicular ultrasounds and tumor markers in blood tests confirmed the diagnoses. The definitive treatments were performed 10 days after the first visit, performing an orchiectomy.

Conclusion: The determination of HCG in high amounts in anti-doping controls in men's soccer, in addition to determining a prohibited substance, can detect testicular tumors early.

Downloads

Download data is not yet available.

References

Kuuranne T, Ahola L, Pussinen Ch, Leinonen A. Analysis of human chorionic gonadotropin (hCG): application of routine immunological methods for initial testing and confirmation analysis in doping control. Drug Test Anal. 2013; 5:614-8.

Stenman U-H, Hotakainen K, Alfthan H. Gonadotropins in doping: pharmacological basis and detection of illicit use. Br J Pharmacol. 2008; 154:569-83.

Fan J, Wang M, Wang C, Cao Y. Advances in human chorionic gonadotropin detection technologies: a review. Bioanalysis. 2017; 9:1509-29.

Fournier T. Human chorionic gonadotropin: Different glycoforms and biological activity depending on its source of production. Ann Endocrinol (Paris). 2016; 77:75-81.

Martínez Brito D, Herrera águila Y, Suárez Pérez Y, Correa Vidal T, Montes de Oca Porto R. La gonadotropina coriónica humana en el dopaje y su control. Estrategia del laboratorio antidoping de La Habana. An Acad Cienc Cuba. 2023; 13:

Stenman U-H, Alfthan H. Determination of human chorionic gonadotropin. Best Pract Res Clin Endocrinol Metab. 2013; 27:783-93.

Berger P, Lapthorn AJ. Standardization of Epitopes for Human Chorionic Gonadotropin (hCG) Immunoassays. Curr Med Chem. 2016; 23:3481-94.

Snyder JA, Haymond S, Parvin CA, Gronowski AM, Grenache DG. Diagnostic considerations in the measurement of human chorionic gonadotropin in aging women. Clin Chem 2005; 51:1830–5.

WADA (World Anti-Dopping Agency). Technical Document – TD2021CG/LH. Descargar: https://www.wada-ama.org/sites/default/files/resources/files/td2021cg-lh_final_eng_0.pdf

Fitch K. Proscribed drugs at the Olympic Games: permitted use and misuse (doping) by athletes. Clin Med (Lond). 2012; 12:257-60.

Cole LA. Human chorionic gonadotropin tests. Expert Rev Mol Diagn. 2009; 9:721-47.

Ferraro S, Panteghini M. A step forward in identifying the right human chorionic gonadotropin assay for testicular cancer. Clin Chem Lab Med 2020; 58:357–60.

Ferraro S, Trevisiol C, Gion M, Panteghini M. Human chorionic gonadotropin assays for testicular tumors: closing the gap between clinical and laboratory practice. Clin Chem 2018; 64:270–8.

Gilligan T, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, et al. American Society of Clinical Oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol 2010; 28:3388–404.

Gronowski AM. Why Is It So Hard to Report Quantitative Human Chorionic Gonadotropin Results? J Appl Lab Med. 2020; 5:847-9.

Robinson N, Sottas P-E, Saugy M. Evaluation of two immunoassays for the measurement of human chorionic gonadotropin in urine for anti-doping purposes. Clin Lab. 2010; 56:197-206.

Butch AW, Woldemariam GA. Urinary human chorionic gonadotropin isoform concentrations in doping control simples. Drug Test Anal. 2016; 8:1147-51.

Lempiäinen A, Hotakainen K, Alfthan H, Stenman U-H. Loss of human chorionic gonadotropin in urine during storage at -20°C. Clin Chim Acta. 2012; 413:232-6.

Tsivou M, Dimopoulou HA, Georgakopoulos DG, Koupparis MA, Atta-Politou J, Georgakopoulos CG. Stabilization of human urine doping control samples: IV. Human chorionic gonadotropin. Anal Bioanal Chem. 2010; 398:1313-8.

Braunstein GD. False-positive serum human chorionic gonadotropin results: causes, characteristics, and recognition. Am J Obstet Gynecol. 2002; 187:217-24.